Monitor blood pressure periodically. Significant bladder outlet obstruction, patients taking antimuscarinic drugs for OAB: risk of urinary retention. Discontinue and treat if angioedema of the ...

Myrbetriq – sold as Betanis and Betmiga in ... with around $650 million in US sales to competition. US sales of the drug plummeted 89% in the first nine months of the current fiscal year.

A US district court has said that a key patent held by Astellas on its Myrbetriq drug for urinary incontinence is invalid, in a setback to its efforts to defend the blockbuster therapy from ...

For this report, we evaluated the following medications: darifenacin (Enablex); fesoterodine (Toviaz); mirabegron (Myrbetriq); oxybutynin (available as a pill [Ditropan XL and generic], a skin ...